Recursion Pharmaceuticals, Inc.
RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.62
Price0.00%
$0.00
1Y
Price
Market Cap
$1.974b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-772.5%
EBITDA Margin-899.8%
Net Profit Margin-416.5%
Free Cash Flow MarginRevenue
$64.441m
+9.5%
1y CAGR+18.0%
3y CAGR+87.7%
5y CAGREarnings
-$648.965m
-40.0%
1y CAGR-39.4%
3y CAGR-38.2%
5y CAGREPS
-$1.78
-5.3%
1y CAGR-9.5%
3y CAGR-14.5%
5y CAGRBook Value
$919.146m
$1.302b
Assets$383.209m
Liabilities$88.075m
DebtDebt to Assets
6.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$391.222m
-4.9%
1y CAGR-59.2%
3y CAGR-34.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company